CORE Biomedicine

CORE Biomedicine announced $21M in Series A financing on July 28, 2026. CORE Biomedicine closed a $21 million Series A co-led by UTokyo Innovation Platform and Elikon Venture, and its Japanese subsidiary received an AMED grant.

Round details

The financing includes backing from UTokyo Innovation Platform, Elikon Venture, InnoPinnacle Fund, Mitsubishi UFJ Capital, Suzhou Capital Group, CD Capital, YuanBio Venture Capital, Vision Incubate. The company did not publish a valuation with the announcement.

• Round: Series A
• Capital announced: $21M

How the company plans to use the capital

CORE Biomedicine said the financing and an AMED grant will advance its lead programs through discovery and early clinical development. The grant, awarded to its Japanese subsidiary, supports research and development and collaboration with Japanese universities, hospitals, and the biopharma community.

Why this matters for GTM teams

The round was co-led by UTokyo Innovation Platform and Elikon Venture, and CORE Biomedicine Japan, a wholly owned subsidiary, received a grant under AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: CORE Biomedicine Series A announcement.